Business Wire

Verimatrix Threat Defense Empowers Capri Healthcare to Safely Digitize Doctor-Patient Care

Share

Regulatory News:

Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that Capri Healthcare chose Verimatrix App Shield, part of Verimatrix’s threat defense business line, to gain fast and proven defenses for its TriVice (triage, referral and advice) mobile app.

TriVice streamlines doctor-patient care by managing acute referrals to specialist clinicians routed through its mobile app. The app captures patient demographics, details of the injury/condition and facilitates the sharing of clinical photographs and images. The app triages and enables sending of Advise and Guidance with an aim to reduce avoidable referrals. Additionally, the app enables real-time notification and communication with referring clinicians as well as integration into existing hospital systems. TriVice makes the referral process easier, smoother, seamless and with better documentation. The app’s goal is to advance the digital-first strategy of the National Health Service (NHS), the publicly funded healthcare system in England.

An automated and self-defending cloud-based solution, Verimatrix App Shield provides Capri Healthcare with peace of mind that staff and patient experiences with its TriVice mobile app are protected against numerous nefarious activities. Though a zero-code (no programming required), SaaS approach, App Shield harden apps and helps prevent hacking attacks such as reverse engineering, application repackaging, dynamic modification, man-in-the-middle attacks and much more.

“Capri Healthcare is an organization driven by the vision of turning the NHS digital-first strategy into reality by bringing digital innovation into the working of healthcare providers,” said Krishna Thakur and Valleesh Athreya, founders at Capri Healthcare. “We are dedicated to using technology to improve care, identifying patient conditions earlier, reducing backlog, digitizing processes and eliminating wasteful tasks. We realize that all of that is only possible if we do so by deploying solutions that are secure and trusted by all. Verimatrix answers that need by quickly and cost-effectively adding enterprise-quality threat defense to our TriVice mobile app.”

“At Verimatrix, we are proud to support innovative organizations such as Capri Healthcare that develop, deploy and accelerate the adoption of breakthrough mobile health experiences that strive to make the world a healthier, better place,” said Asaf Ashkenazi, Chief Operating Officer and President at Verimatrix. “We are especially pleased to work with healthcare innovators like Capri Healthcare, as practitioners and patients alike see privacy and security as a standard expectation, especially as new digital processes are established and adopted. This announcement proves again that Verimatrix’s threat defense solutions are essential for the global healthcare market that is rapidly adopting mobile technologies.”

About Capri Healthcare
Capri Healthcare is an organization driven by the vision of turning the NHS Digital First strategy into reality by bringing digital innovation to healthcare providers. Leading healthcare organizations into the digital era by redesigning and developing patient-centric online systems (web & mobile), Capri Healthcare helps significantly reduce the burden on staff as well as the NHS. The company prides itself in offering a range of technology-driven innovative solutions that drive the healthcare industry’s digital agenda. Visit www.caprihealthcare.co.uk.

About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Verimatrix Investor Contact:
Jean-François Labadie, Chief Financial Officer
finance@verimatrix.com

Verimatrix Media Contact:
Matthew Zintel
matthew.zintel@zintelpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye